Johnson & Johnson
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Johnson & Johnson is a global healthcare company engaged primarily in the research, development, manufacture, and sale of a broad range of pharmaceutical, medical device, and consumer health products. The company operates segments including Pharmaceuticals, Medical Devices, and Consumer Health, offering products such as prescription medicines for immunology, oncology, neuroscience, infectious diseases; orthopedic and surgical devices; and branded consumer healthcare products like Band-Aid and Listerine. Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson serves customers worldwide across multiple markets. Recent major changes include Johnson & Johnson's 2025 acquisition of neurological drug maker Intra-Cellular Therapies for approximately $14.6 billion, expanding its neuroscience portfolio. In November 2025, J&J also announced the acquisition of Halda Therapeutics for $3.05 billion to bolster its oncology pipeline with innovations targeting metastatic castration-resistant prostate cancer. The company launched new cancer therapies Vykt, Tecvayli, and Talvey targeting multiple myeloma, generating $1.3 billion in sales in the first half of 2025. Furthermore, J&J is advancing drug candidates such as nipocalimab (Imaavy) for immune-mediated disorders and Caplyta for bipolar depression. The company also plans to divest its consumer health segment, signaling a strategic shift to focus more intensively on pharmaceuticals and medical devices. Johnson & Johnson continues to pursue regulatory approvals and expand indications for key drugs including SIMPONI, STELARA, TREMFYA, and Caplyta. It projects peak sales of several pipeline candidates at approximately $5 billion each. The firm remains heavily invested in research and development across immunology, oncology, neuroscience, and autoimmune diseases, leveraging innovative technologies including adenovirus vector and mRNA platforms. Johnson & Johnson reported a 6.8% sales increase to $24 billion in Q3 2025, reflecting operational growth driven by its pharmaceutical segment. This combination of advanced product portfolios, strategic acquisitions, and selective divestitures positions Johnson & Johnson as a leading global medical and pharmaceutical company focused on delivering innovative therapeutic solutions worldwide. The company's broad geographic operations span North America, Europe, Asia-Pacific, and emerging markets, catering to diverse healthcare needs across prescription drugs, medical devices, and consumer health products.
Company News
Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.
Evolve Private Wealth LLC Has $7.96 Million Holdings in Johnson & Johnson $JNJ
GQG Partners LLC Sells 7,292,131 Shares of Johnson & Johnson $JNJ
Emerald Investment Advisers LLC Purchases 7,121 Shares of Johnson & Johnson $JNJ
Compass Financial Management LLC Makes New Investment in Johnson & Johnson $JNJ
Daiichi Life Insurance Co. Ltd. Acquires 8,767 Shares of Johnson & Johnson $JNJ
Clear Harbor Asset Management LLC Lowers Holdings in Johnson & Johnson $JNJ
Commerce Bank Increases Position in Johnson & Johnson $JNJ
Haverford Trust Co Sells 22,652 Shares of Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Shares Sold by Farringdon Capital Ltd.
Barrow Hanley Mewhinney & Strauss LLC Sells 5,519 Shares of Johnson & Johnson $JNJ
Bank of Nova Scotia Buys 124,651 Shares of Johnson & Johnson $JNJ
J&J Gains as AbbVie Posts 74% Myeloma Response
Hikari Tsushin Inc. Has $27.70 Million Position in Johnson & Johnson $JNJ
EP Wealth Advisors LLC Acquires 97,152 Shares of Johnson & Johnson $JNJ
Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
J&J Jumps as UBS Lifts Its Target to $320
J&J Faces Multiple Headwinds: Can the Healthcare Giant Sustain Growth?
Johnson & Johnson Replaced $913 Million In Lost Sales With $2.4 Billion In New Ones - But Kept Less Than Half
D L Carlson Investment Group Inc. Has $6.82 Million Stock Position in Johnson & Johnson $JNJ